• ELISA Solution
    for COVID-19 Diagnosis

    COVID-19 ELISA IgM+IgA · COVID-19 ELISA IgG


  • VirClia®, the True Monotest
    for COVID-19 Diagnosis

    COVID-19 VIRCLIA IgM+IgA MONOTEST
    COVID-19 VIRCLIA IgG MONOTEST


  • Coronavirus
    New SARS-CoV-2 RealTime PCR kit

    Specific for COVID-19 and SARS- related coronavirus


  • AMPLIRUN® SARS-CoV-2
    Amplification Controls

    Guarantee the quality of your COVID-19
    molecular assays


  • SARS-COV-2
    Picture from Vircell culture collection


Featured product

COVID-19 VIRCLIA®

COVID-19 VIRCLIA®

COVID-19

Vircell team is fully committed to help stop the spread of the Coronavirus. Let's fight together!

More information

Development and production of diagnostic reagents for human infectious diseases

Vircell is a biotechnology company specialized in the development and production of ready to use reagents for human infectious diseases. We are present in laboratories of more than 80 countries worldwide on five continents. Vircell offers more than 400 references for the detection of bacteria, viruses, parasites and fungi by means of different techniques: ELISA, chemiluminescence, direct and indirect immunofluorescence, immunocapture agglutination, cell culture and Molecular Biology (oligochromatography and PCR controls).

Distributors

Vircell is present in laboratories of more than 80 countries worldwide. International Sales constitute one of the major sources of income for the company thanks to the constant work of our commercial team, who has a deep knowledge of the international market. If you need further information on the distribution of our products in your country, do not hesitate to contact us.

More information
24 November 2020 Vircell increases its production capacity of reagents for the diagnosis of COVID-19 Vircell receives the grant of the Ministry of Industry, Commerce and Tourism based on Order ...
16 November 2020 MEDICA 2020 Vircell will be attending, once again, the biggest medical fair in the world next November ...

Newsletter

Sign up for our newsletter and you will receive our latest news in your e-mail